SQY Therapeutics’ Post

SFBN Feed: Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD) https://lnkd.in/gE-eJJy7 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VGA039 in von [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Pharmaceutical companies are heavily investing in therapies that target proteins for degradation. A new class of therapies known as PROTAC protein degraders (PROTAC is an acronym of ‘proteolysis targeting chimera’ and has been trademarked by Arvinas) are now progressing into late stage clinical trials. A PROTAC is not a classic enzyme inhibitor. Instead, it promotes degradation of the targeted protein via the proteasome. With this concept even previously undruggable proteins can be targeted for degradation via proteolysis. #pharma #drugdevelopment #proteindegrader #PROTACS

Pharmaceutical companies are heavily investing in therapies that target proteins for degradation. A new class of therapies known as PROTAC protein degraders (PROTAC is an acronym of ‘proteolysis targeting chimera’ and has been trademarked by Arvinas) are now progressing into late stage clinical trials. A PROTAC is not a classic enzyme inhibitor. Instead, it promotes degradation of the targeted protein via the proteasome. With this concept even previously undruggable proteins can be targeted for degradation via proteolysis. #pharma #drugdevelopment #proteindegrader #PROTACS

Two must-attend sessions at the Oligonucleotide Therapeutics Xchange - Maryland 2024, 30 October, that you won't want to miss! Secure your free pass: https://lnkd.in/eWms8KbQ 🎯 Sponsor-led Roundtable Discussion: "Manufacturing n-of-1 Batches - Helping 1 Patient at a Time?" ⏰ 11:25 AM - 12:25 PM Join us for a sponsor-led roundtable discussion where we'll delve into the intricacies of manufacturing n-of-1 batches—a groundbreaking approach that could revolutionize personalized medicine, one patient at a time. This is a unique opportunity to engage with industry experts, exchange ideas, and explore innovative strategies in oligonucleotide manufacturing. 🎤 Poster Presentation: "Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs Compatible With Conventional Automated Oligonucleotide Synthesis" ⏰ 3:15 PM - 3:45 PM Presented by Jeremy Little, Director of Custom Oligonucleotides at ChemGenes this session will showcase the latest advancements in TMOs—a novel class of PMOs that are set to enhance oligonucleotide synthesis. With over a decade of experience in nucleic acid drug discovery and oligonucleotide manufacturing, Jeremy brings unparalleled expertise to the table. Whether you're involved in biotech, pharma, or are just passionate about the future of oligonucleotide therapeutics, these sessions are invaluable. 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #LifeSciences #PrecisionMedicine #NucleicAcids #Pharmaceuticals #MedicalInnovation #Healthcare #Biotechnology #DrugDevelopment #MolecularBiology #ScientificResearch #GeneTherapy #OligonucleotideSynthesis #Biopharma #FutureOfMedicine #BiotechIndustry #InnovationInHealthcare #PharmaResearch #MedicinalChemistry #ClinicalResearch #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

The field of siRNA therapeutics is rapidly expanding, driven by advancements in RNAi technology and the success of FDA-approved drugs from key players like Alnylam Pharmaceuticals. 🌟   However, major challenges remain, particularly in delivering siRNA molecules to sensitive target cells. Their hydrophilic, negatively charge nature makes cellular uptake difficult. 🔬   While delivery systems like lipid nanoparticles (LNPs) and GalNAc conjugates have been developed, further improvements are necessary. 🚀 Additionally, off-target effects and immune responses pose significant hurdles. 🚧 Chemical modifications to siRNA can enhance stability and reduce immunogenicity, but ongoing research is crucial. 📚   CapCoBIO can help tackle these challenges. Feel free to ask for a 💎 𝐬𝐢𝐑𝐍𝐀-𝐂𝐀𝐏𝐒𝐔𝐋𝐎𝐍💎  sample kit! 🧬✨     #siRNA #RNAi #genetherapy #innovation #biotechnology

🌟 Unlock Insights into the #PhenylketonuriaMarket! 🌟 The global #PhenylketonuriaMarket is evolving with new advancements in treatment options, diagnostics, and therapies. As researchers work towards expanding access to innovative solutions, the market is expected to witness substantial growth. The leading #PhenylketonuriaCompanies such as BioMarin Pharmaceutical Inc. Synlogic, PTC Therapeutics, Inc. Jnana Therapeutics, Homology Medicines, Inc, Nestlé Health Science, Moderna, SOM Biotech, Agios Pharmaceuticals, APR Applied Pharma Research s.a. American Gene Technologies® International Inc., Generation Bio, and others. Stay ahead of the curve with DelveInsight Business Research LLP's comprehensive analysis of the #PhenylketonuriaMarket. 🔗 Explore More @ https://lnkd.in/dSa6FErt #Phenylketonuria #PKUMarket #Healthcare #RareDiseases #Biotech #Pharma #DelveInsight #MarketAnalysis #MedicalResearch

It's been approximately five years since the first PROTAC degraders (vepdegestrant and bavdegalutamide) entered clinical trials. Since this milestone, Targeted Protein Degradation and its therapeutic applications have continued to advance rapidly – and this trend shows no sign of slowing down anytime soon!      If you want to catch up on the state of the TPD world, check out our most recent blog post: https://lnkd.in/dwB7u_Jj     Inside, you'll find all the information you need to…  💡...understand the unique advantages of TPD-based strategies.   💡…evaluate the clinical successes of existing PROTAC drugs.   💡… forecast the promising future of TPD therapeutics based on an extensive body of exciting pre-clinical research.      And if you're ready to take advantage of the power of TPD to accelerate your drug discovery project, contact us at momentum.bio/contact    #TPD #PROTAC #DrugDiscovery #Biotech 

𝐍𝐞𝐞𝐝 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬? 𝐖𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫! For over 30 years, Intavis Peptide Services has been a leading expert in the peptide industry. Renowned for producing 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐜𝐮𝐬𝐭𝐨𝐦 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬, as well as pioneering 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬, we conduct all our production and services in our state-of-the-art facilities in Tübingen, Germany. In case you are planning in-vitro peptide research or a clinical trial on peptide therapeutics talk to our expert advisors now! Find the link in the comment. #ClinicalPeptides #PeptideProduction #Biotechnology #peptides

Precision and speed matter in preclinical bioanalysis. Our latest Application Note dives into how the Gyrolab® 2G Generic PK Kit enhances both. 📊 Download it now! #Biotech #Bioanalysis #pharmacokinetics https://lnkd.in/gNf6tTiu

The demand for more targeted therapeutics, such as antibody drug conjugate's (ADC), has rose significantly over the last few years as our grasp on protein engineering as increased. These ADC's have a more complex structure compared to traditional antibodies making it crucial to monitor not only the overall impurities during the production process, but also the charge variant profiles as well to ensure product quality. The workflow below demonstrates the breakthrough technology of the BioPhase 8800 system to be able to monitor purity as well as charge of your ADC on a single, high throughput, instrument. Take a look at what SCIEX is doing to help scientist in developing these critical therapeutics. ⬇ #SCIEX #CE #ADC #antibody #biopharma #BioPhase #danaher #proteins